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Brief Definit ive Report
Evolutionarily conserved signaling pathways 
and cell fate determinants, such as RNA-binding 
proteins or polarity regulators, have been re-
cently described as effectors in hematopoietic 
stem cell (HSC) biology (Wu et al., 2007; Hope 
et al., 2010; Ito et al., 2010; Kharas et al., 2010). 
However, only a few members of the polarity 
network have been investigated to date, and the 
exact role of these genes in HSCs and leukemia 
is not well understood. Several genes and sig-
naling pathways control the fine balance be-
tween self-renewal and differentiation in HSCs 
and potentially also in leukemia stem cells 
(LSCs; Heidel et al., 2011). For example, knock-
down of select polarity-associated genes leads 
to enhanced (Prox1) or decreased (Pard6a, 
Prkcz, and Msi2) repopulation potential of HSCs 
in vivo. Llgl1 (lethal giant larvae homolog 1) is 
a highly conserved gene, known to be involved 
in regulation of cell polarity, proliferation, and 
cell division. It connects the polarity nodes “Par 
complex” (Pard6, Pard3, and Prkcz/Prkci) and 
“Scribble complex” (Dlg, Scrib, and Llgl1), 
components of which have been shown to in-
fluence the repopulation capacity of HSCs 
(Humbert et al., 2006). This network has been 
reported to interact with several stem cell rele-
vant pathways, such as canonical Wnt signaling, 
Notch signaling, and Hippo pathway signaling 
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A unique characteristic of hematopoietic stem cells (HSCs) is the ability to self-renew. 
Several genes and signaling pathways control the fine balance between self-renewal and 
differentiation in HSCs and potentially also in leukemia stem cells. Recently, studies have 
shed light on developmental molecules and evolutionarily conserved signals as regulators of 
stem cells in hematopoiesis and leukemia. In this study, we provide evidence that the cell 
fate determinant Llgl1 (lethal giant larvae homolog 1) plays an important role in regulation 
of HSCs. Loss of Llgl1 leads to an increase in HSC numbers that show increased repopula-
tion capacity and competitive advantage after transplantation. This advantage increases 
upon serial transplantation or when stress is applied to HSCs. Llgl1/ HSCs show increased 
cycling but neither exhaust nor induce leukemia in recipient mice. Llgl1 inactivation is 
associated with transcriptional repression of transcription factors such as KLF4 (Krüppel-
like factor 4) and EGR1 (early-growth-response 1) that are known inhibitors of HSC self-
renewal. Decreased Llgl1 expression in human acute myeloid leukemia (AML) cells is 
associated with inferior patient survival. Thus, inactivation of Llgl1 enhances HSC self-
renewal and fitness and is associated with unfavorable outcome in human AML.
© 2013 Heidel et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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competitive advantage of 10-fold when compared with 
Llgl1+/+ cells. The competitive advantage in peripheral blood 
chimerism increased in secondary (Fig. 1 E) and tertiary 
recipient mice (Fig. 1 F). This increase in chimerism was also 
detectable in total BM (Fig. 1, G and H, left) or HSC (CD34lo 
LSK cells; Fig. 1, G and H, right) populations. In tertiary 
recipients, the HSC pool was almost exclusively repopu-
lated with cells from the Llgl/ mice, whereas in BM cells 
of the myeloid lineage, cells from Llgl1+/+ control mice al-
most disappeared (Fig. 1 I). This gain in self-renewal capacity 
could potentially lead to the development of leukemia; 
however, none of the mice developed leukemia during serial 
transplantation up to 12 mo after conditional deletion of Llgl1 
(not depicted).
This phenotype might be explained by improved homing 
of Llgl1 deleted cells or by transplantation of increased HSC 
numbers. Therefore, we transplanted “undeleted” (CD45.1) 
BM cells derived from Llgl1loxP/loxP Mx-Cre+ mice or Llgl1loxP/loxP 
Mx-Cre mice competitively (1:1) into C57BL/6 recipients 
and assured equal engraftment levels after 4 wk (Fig. 2 A). 
This ensured that even without differences in homing or cell 
numbers, Llgl1/ cells would still compete better in this ex-
periment. Mice were then treated with pIpC to inactivate Llgl1. 
In this setting, a competitive advantage for Llgl1/ BM cells 
could still be detected and increased after transplantation into 
secondary recipient mice (Fig. 2 A).
To assess whether HSC frequency contributed to the com-
petitive advantage, we performed limiting dilution experi-
ments using whole BM cells shortly after deletion of Llgl1. 
BM of Llgl1/ mice and Llgl1+/+ littermates (50,000, 10,000, 
5,000, and 2,500 cells) were injected into lethally irradiated 
(11 Gy) C57BL/6 recipients along with 500,000 (CD45.1/2 
double positive) competitor cells from age-matched controls. 
BM chimerism was analyzed at week 14. Calculating the stem 
cell frequencies, the Llgl1 WT cohort showed a frequency 
of 1/28,346 (95% CI 0.0000146 to 0.0000855) and the Llgl1 
KO cohort 1/18,156 (95% CI 0.0000253 to 0.0001198; 
Fig. 2 B). This indicates that cell numbers (through expansion 
of HSCs) do contribute to the increase in chimerism, at least 
to some extent. Besides that, homing of LSK cells, as detected 
16 h after injection into lethally irradiated mice, was not dif-
ferent between Llgl1/ cells compared with Llgl1+/+ controls 
(Fig. 2 C). Therefore, a potential difference in homing capacity 
cannot fully explain the enhanced repopulation capacity of 
Llgl1/ HSCs.
Next, we aimed to investigate distinct stressors of HSCs 
to determine the extent to which Llgl1 loss appears to be 
protective for HSCs. Ex vivo culture of HSCs is known to 
decrease stem cell numbers, viability, and repopulation ca-
pacity (Perry et al., 2011). Augmentation of ex vivo culture 
is therefore an attractive therapeutic approach in trans-
plantation biology. Stress was applied by ex vivo culture of 
Llgl1/ or Llgl1+/+ BM cells for 5 d. Transplantation of 
these cells into primary recipient mice at limiting dilutions 
revealed a significantly increased percentage of repopulating 
Llgl1/ donor cells in the peripheral blood compared with 
(Humbert et al., 2006; Menéndez et al., 2010). Recently, 
atypical protein kinases ( and ) have been reported to be 
dispensable in HSCs (Sengupta et al., 2011). However, few 
other polarity proteins have been investigated for a role in 
hematopoietic cells. In Drosophila melanogaster, deletion of 
Llgl1 results in neoplastic proliferation and loss of polarity of 
imaginal epithelia and neuroblasts (Gateff, 1978). In Drosoph-
ila, Llgl1 was the first in vivo example of a gene in which loss 
of function resulted in tumor formation and is therefore dis-
tinct from most other transforming oncogenes, which are 
frequently overexpressed (Gateff, 1978). Pronounced simi-
larities with Drosophila Llgl1 mutants were also found in 
Llgl1-KO mice. Llgl1/ mice presented at birth with severe 
brain dysplasia caused by the loss of cell polarity, increased 
self-renewal, and decreased differentiation of neural progenitor 
cells (Klezovitch et al., 2004). In clinical samples, loss of Llgl1 
expression is associated with a variety of epithelial and mes-
enchymal cancers (Ohali et al., 2004; Schimanski et al., 2005; 
Kuphal et al., 2006; Lu et al., 2009). Recently, mutations of 
Llgl2, a close human homologue of Llgl1, have been found 
in progression from severe congenital neutropenia to acute 
myeloid leukemia (AML; Beekman et al., 2012).
In this project, we investigated a potential role for Llgl1 in 
HSCs via genetic inactivation of Llgl1. Loss of Llgl1 leads to 
expansion of HSCs in steady-state hematopoiesis and to 
enhanced repopulation capacity after serial transplantation or 
stress. Llgl1 loss influences several known transcriptional acti-
vators involved in HSC self-renewal, and decreased LLGL1 
expression is associated with poor prognosis in human AML.
RESULTS AND DISCUSSION
Inactivation of Llgl1 increases HSC number and fitness in vivo
As disruption of evolutionarily conserved polarity regulators 
may impact HSC biology, we aimed to investigate the role 
of Llgl1 in steady-state hematopoiesis. We injected poly-I–
poly-C peptide (pIpC) into Llgl1loxP/loxP Mx-Cre+ mice or the 
corresponding littermate controls (Llgl1+/loxP Mx-Cre+, Llgl1+/+ 
Mx-Cre+, or Llgl1loxP/loxP Mx-Cre mice) to induce genetic 
deletion of Llgl1. Over the next 16 wk, we monitored periph-
eral blood counts and did not find any significant abnor-
malities after conditional deletion of Llgl1 except a mild 
lymphocytosis 4 wk after pIpC (Fig. 1 A). Efficient excision of 
Llgl1 was confirmed in the BM by PCR. However, immuno-
phenotypic analysis of the BM 16 wk after pIpC treatment 
revealed a significant increase in long-term HSCs (LT-HSCs; 
lineage, Sca-1+, Kit+ [LSK], CD34lo, Flk2). This increase 
was also found in the lineage, Sca-1+, Kit+, CD34lo, Flk2, 
CD48 (SLAM+) population (Fig. 1, B and C), which is the 
most highly enriched LT-HSC population described so far 
(LT-HSC frequency 1:2; Kiel et al., 2005). When whole BM 
cells were transplanted into primary recipient mice in a com-
petitive fashion at a ratio of 1:1 (and also 9:1 [not depicted]; 
control vs. test BM) on week 16, we found that Llgl1/ cells 
competed significantly better than Llgl1+/+ controls as indi-
cated by increased chimerism (Fig. 1 D). This data suggests a 
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status might occur after Llgl1 deletion. In most cases where 
more HSCs are found to be actively cycling, this ultimately 
leads to exhaustion of the HSC pool. However, two recent 
gene KO models have been published showing increased 
(Rathinam et al., 2011) or unchanged (Park, C.S., et al. 2011. 
American Society of Hematology Annual Meeting and Ex-
position. Abstr. 861.) cell cycle activity in HSCs while con-
ferring enhanced fitness and competitive advantage to stem 
cells. Genetic inactivation of the E3 ubiquitin ligase Itch led 
to increased cell cycle activity of HSCs through activation 
of Notch signaling without affecting the long-term repopu-
lation activity of HSCs (Rathinam et al., 2011). Deletion of 
the transcription factor Klf4 (Krüppel-like factor 4) did not 
WT cells (Fig. 2 D) 4 wk after transplantation. Analysis of 
BM and stem cell fractions displayed a similar degree of 
enhanced repopulation capacity 16 wk after transplantation 
(Fig. 2 E). These experiments confirm enhanced function of 
Llgl1/ HSCs that appears to increase after stress and even-
tually leads to radioprotection of lethally irradiated recipi-
ent mice. Survival was increased for Llgl1/ versus Llgl1+/+ 
at levels of 105 cells (100 vs. 71.4%) and 104 cells (100 vs. 
33.3%; (Fig. 2 F).
Llgl1 protects quiescence of LT-HSCs
As loss of Llgl1 was associated with an increase of LT-HSC 
numbers in vivo, we assessed whether changes in cell cycle 
Figure 1. Loss of Llgl1 increases the amount and competitive advantage of HSCs. (A) Peripheral blood counts after conditional deletion of 
Llgl1 during steady-state hematopoiesis. (B and C) Numbers of HSCs (CD34lo, Flk2 LSK and CD34lo, Flk2 CD48 SLAM+ LSK) 16 wk after deletion. 
(D and G) Llgl1/ cells competed better against WT competitor cells (Llgl1+/+ littermate controls) in peripheral blood (D)– and BM-HSC chimerism (G; two 
independent cohorts; n > 4 per cohort). (E, F, H, and I) Increase of competitive advantage over time throughout serial transplantations in total BM and 
HSCs of secondary (E and H) and tertiary (F and I) recipient mice (secondary and tertiary recipients received total unfractionated BM from primary recipi-
ent mice). (E and H) Horizontal lines represent the mean of each group. Error bars indicate the standard deviation. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Llgl1 inactivation leads to transcriptional repression  
of KLF4 and EGR1 (early-growth-response 1)
To identify potential downstream effectors of Llgl1 loss, we 
performed gene expression profiling (GEP) on HSCs (Flk2 
LSK) 10 wk after conditional deletion of Llgl1 in steady-state 
hematopoiesis. The top 50 deregulated genes are displayed 
in Fig. 4 A. Several of the genes that change expression in 
the absence of Llgl1 have already been implicated in stem 
cell biology. The most prominent effectors are Klf4 and Egr1 
(Fig. 4 A). Loss of Klf4 leads to increased stem cell numbers, 
self-renewal capacity, and survival of stressed HSCs (Park, 
C.S., et al. 2011. American Society of Hematology Annual 
Meeting and Exposition. Abstr. 861.). This advantage increases 
over serial transplantations. Moreover, KLF4 has recently been 
shown to be a repressed target in CDX2-induced AML 
development (Faber et al., 2012). Egr-1 revealed significant 
increase of HSCs in the BM of the respective KO mice (Min 
et al., 2008). However, enhanced cycling and proliferation of 
Egr1/ HSCs eventually led to exhaustion of the HSC pool. 
In our model, Llgl1/ HSCs do not exhaust although more 
HSCs are in the cell cycle. This may be caused by compensa-
tory effects, for example, via up-regulation of other target 
genes such as Hox genes (e.g., Pbx3; Fig. 4 A), tyrosine kinases 
(e.g., Yes, associated with Hippo-signaling), or other enzymes 
(e.g., the oxidosqualene cyclase Lss) that are known mediators 
of stem cell self-renewal and protection (Faber et al., 2009; 
Mejia-Pous et al., 2011; Tamm et al., 2011; Li et al., 2012).
cause any changes in cell cycle activity but also led to im-
proved HSC capacity through protection from apoptosis 
(Park, C.S., et al. 2011. American Society of Hematology 
Annual Meeting and Exposition. Abstr. 861.). Thus, we in-
vestigated whether conditional inactivation of Llgl1 would 
influence cell cycle status in HSCs, multipotent progenitors 
(MPPs), and more differentiated progenitors such as com-
mon myeloid progenitors (CMPs), granulocyte macrophage 
progenitors (GMPs), or megakaryocyte erythroid progenitors 
(MEPs). Ki-67 staining in steady-state hematopoiesis revealed 
a significant increase in the number of cycling Llgl1/ HSCs 
as compared with Llgl1+/+ HSCs (Fig. 3, A and B). This effect 
was not evident in MPPs, GMPs, or MEPs (Fig. 3 B). This 
cell cycle analysis was performed 16 wk after pIpC injec-
tion. To investigate these effects at an earlier time point, we 
injected mice with pIpC and then assessed BrdU incorpo-
ration 3 wk later. To avoid stem cell toxicity by BrdU incor-
poration, we analyzed the BM of injected mice early (18 h) 
after BrdU injection. Consistent with our findings using 
Ki-67 staining, more Llgl1/ HSCs were cycling than 
Llgl1+/+ controls (Fig. 3 C). This indicates increased cell 
cycle activity of HSCs upon inactivation of Llgl1 without 
exhaustion of the stem cell pool. Thus, the stem cell com-
partment rather increased and gained repopulation capacity. 
This could be an indicator of an increase in symmetric (vs. 
asymmetric) stem cell divisions, leading to an increase of the 
stem cell number.
Figure 2. Enhanced HSC fitness after genetic inactiva-
tion of Llgl1 is independent of engraftment and detect-
able after ex vivo culture. (A) Conditional deletion of Llgl1 
4 wk after transplantation of previously undeleted cells. 
Competitive advantage of Llgl1/ cells (compared with WT 
controls) in vivo in primary (left) and secondary (right)  
recipient mice (two independent cohorts, n > 3 per cohort) is 
shown. (B) Limiting dilution assay. Increased frequency of 
HSCs in Llgl1/ cohorts compared with WT controls 14 wk 
after transplantation is shown. (C) Homing of LSK cells in 
lethally irradiated recipient mice. (D and E) Repopulation 
capacity of Llgl1/ cells after ex vivo culture of HSCs for 5 d. 
(D) Peripheral blood chimerism at 4 wk. *, P < 0.05; **, P < 0.01. 
(E) BM and HSC chimerism 16 wk after transplantation  
(two independent cohorts; >7 mice/dilution). (F) Radiopro-
tection of lethally irradiated recipient mice (survival after  
ex vivo culture of transplanted HSCs). Error bars indicate the 
standard deviation.
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the top differentially expressed cell fate determinate was Llgl1, 
and its loss was associated with both LMPP-like and GMP-like 
LSC signatures when compared with their normal counter-
parts (Fig. 4 E and not depicted). As we found the Llgl1/ sig-
nature to be prognostically relevant in a group of predominantly 
CN-AML, we asked whether repression of Llgl1 itself could be 
associated with outcome. Therefore, we investigated two inde-
pendent patient cohorts treated for CN-AML in two different 
AML study groups by GEP and quantitative PCR, respectively. 
We analyzed 83 patients below the age of 60 with CN-AML 
(AMLSG study group) using gene expression analysis. Here, 
we dichotomized the Llgl1 expression data and compared sur-
vival of the high expressing (upper 50%) with the low express-
ing (lower 50%) cohort. This analysis revealed significantly 
decreased overall survival in the low expressing group (**, P = 
0.0092; Fig. 4 G). This is an important indicator for Llgl1 play-
ing a role in disease biology of CN-AML. Multivariable analy-
sis using a COX regression model proved Llgl1 expression to 
be of prognostic relevance independent of known prognostic 
factors such as FLT3-ITD, NPM1, or CEBPa mutation sta-
tus. To confirm the GEP data, we analyzed Llgl1 expression by 
quantitative RT-PCR (qRT-PCR) and found a wide range 
of expression throughout CN-AML samples (Fig. 4 F). Using 
an independent cohort of 80 patients treated for CN-AML in the 
OSHO study group with standard chemotherapy we screened 
LLGL1 expression by qRT-PCR. We were able to confirm a 
significantly inferior survival in the LLGL1lo cohort (**, P = 
0.0056; Fig. 4 H).
Loss of Llgl1 is involved in disease development  
and influences prognosis of human AML
Decreased Llgl1 expression has been previously shown to 
be associated with increased metastatic potential, malignant 
phenotype, or inferior survival in a variety of solid tumors 
(Ohali et al., 2004; Schimanski et al., 2005; Kuphal et al., 2006). 
Given that Llgl1 restrains self-renewal in HSCs and that leuke-
mia is characterized by aberrant activation of self-renewal, we 
assessed for a role in human AML. First, we asked whether the 
gene expression signature revealed by genetic inactivation of 
Llgl1 (Llgl1/ signature) in HSCs was associated with any 
genetic subtypes of primary AML. Indeed, clustering based on 
the Llgl1/ signature (Fig. 4 B) grouped AML cases into sub-
groups significantly associated with cytogenetic abnormalities 
(Fig. 4, B and C). Especially core-binding factor leukemias 
(t(8;21) and inv(16)) or t(15;17) clustered into specific sub-
groups. Moreover, the Llgl1/ signature was most strongly 
correlated with group 7 based on hierarchical clustering. This 
group contained mostly cytogenetically normal leukemias 
(Fig. 4, B and C). Interestingly, this group (enriched for the 
Llgl1/ signature) also correlated with decreased survival 
as compared with the other leukemia subgroups (Fig. 4 D). 
To confirm this potential relevance for disease biology and 
prognosis in cytogenetically normal AML (CN-AML), we first 
screened for differences in Llgl1 expression levels using a 
recently published GEP dataset. This dataset described the 
coexistence of lymphoid-primed MPP (LMPP)–like and GMP- 
like LSCs in human AML (Goardon et al., 2011). Of interest, 
Figure 3. Llgl1 protects quiescence of 
LT-HSCs. (A and B) HSC cell cycle in steady-
state hematopoiesis after genetic inactivation 
of Llgl1. (B) Distribution of cell cycle phases in 
HSCs (34lo LSK), MPPs, GMPs, or MEPs (2 co-
horts, n = 6) after genetic inactivation of 
Llgl1. Error bars indicate the standard devia-
tion. *, P < 0.05. (C) Short-term BrdU incorpo-
ration confirms stem cell cycling in vivo.
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of the German–Austrian AMLSG study group. Samples for qRT-PCR analy-
sis of Llgl1 expression were obtained within the AML trials (OSHO-2003) 
of the East German Study Group (OSHO) including the Hematology Tumor 
Bank Magdeburg (HTM) and approved by the respective local ethics com-
mittee (Ethics Committee of the Otto-von-Guericke University Magdeburg 
and Ethics Committee of the University of Ulm). Human leukemia cell lines 
were purchased from the American Type Culture Collection or DSMZ.
LLGL1 expression analysis. LLGL1 and ABL as endogenous control for 
each sample were analyzed in triplicate on the same 96-well plate using a 
7300HT real-time PCR machine (Applied Biosystems). Expression levels 
were determined by SYBR-green using the following primers: Llgl_Q-fw, 
In summary, we provide evidence that decreased Llgl1 
expression is associated with a poor prognosis in human AML. 
Conditional deletion of Llgl1 in vivo leads to expansion of 
LT-HSCs, increased fitness, and competitive advantage of 
HSCs. These data support a role for stem cell–associated 
properties as critical for human leukemia development and 
treatment response.
MATERIALS AND METHODS
Primary patient samples and human leukemia cell lines. For gene 
expression analysis (GEP), 83 primary AML patient samples with normal 
karyotype (CN-AML) were obtained within the AML trials (AMLSG07-04) 
Figure 4. Llgl1 acts upstream of tran-
scriptional activators of self-renewal  
capacity, and its repression is associated 
with leukemia development and an  
adverse prognosis in CN-AML. (A) GEP on 
HSCs (Flk2 LSK) after conditional deletion of 
Llgl1 in steady-state hematopoiesis (14-wk-
old mice, 10 wk after pIpC administration). 
The top 25 up- or down-regulated genes (by 
fold change) are displayed. (B) Hierarchical 
clustering of 436 AML cases along with the 
Llgl1/ signature. hc groups, hierarchical 
cluster–defined groups. (C) Clustering based 
on the overlap for the top 200 genes reveals a 
significant grouping into karyotype-associ-
ated groups (P < 0.001). The Llgl1/ signa-
ture clusters with a CN-AML predominated 
subgroup. (D) The Llgl1/ signature–associated 
subgroup is associated with inferior outcome 
(P = 0.0089). (E) GEP during development  
of LMPP and GMP into their malignant coun-
terparts reveals Llgl1 to be the top down-
regulated cell fate determinant. Expression of 
Llgl1 is reduced in LMPP-AML compared with 
LMPP and in GMP-AML compared with GMP.  
(F) Primary AML samples show a high variabil-
ity in Llgl1 expression. AML patient samples 
reveal a decreased expression in AML when 
compared with the MPD cases or normal 
granulocytes. Error bars indicate the standard 
deviation. (G) Low expression of Llgl1 as mea-
sured by Affymetrix gene arrays was associ-
ated with decreased survival in 83 karyotypic 
normal AML (CN-AML) patients below the age 
of 60 yr (AMLSG). (H) This finding could be 
confirmed in an independent CN-AML cohort 
(n = 80; OSHO study group) by qRT-PCR (all 
patient samples measured in triplicate).
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(Invitrogen) was used for cell cycle analysis with Ki-67 according to the 
manufacturer’s protocol.
In vivo BrdU incorporation assay. Llgl1/ or Llgl1+/+ mice were in-
jected i.p. with 180 µl BrdU/PBS solution (10 mg/ml; BrdU kit; BD). 18 h 
after injection, BM cells were harvested and stained with lineage and second-
ary antibodies as indicated above.
RNA amplification and gene expression array. RNA was isolated from 
104 sorted HSCs (Lineage, Kit+, Sca-1+, Flk2) using TRIzol (Invitrogen). 
RNA was amplified using the Ovation Pico WTA system (Nugen) and labeled 
using the Encore Biotin Module (Nugen). 5 µg of amplified and labeled DNA 
was hybridized to Affymetrix 430 2.A mouse microarrays.
Statistics and analysis of gene expression data. For survival analysis, 
Kaplan–Meier curves were plotted using Prism version 5.00. Differences be-
tween survival distributions were analyzed using the logrank test. Statistical 
analyses were performed using the Student’s t test (normal distribution) or 
Mann–Whitney U test (when normal distribution was not given). P < 0.05 
was considered statistically significant (P < 0.05 indicated as *, P < 0.01 in-
dicated as **, and P < 0.001 indicated as ***). Published gene expression 
datasets (GSE16432 [Wilson et al., 2009] and GSE15434 [Kohlmann et al., 
2010]) were downloaded from GEO. Primary gene expression data were 
provided by Goardon et al. (2011). Gene expression data were normalized 
and analyzed as previously reported (Lück et al., 2011).
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